Advertisement

Topics

Latest Urology NewsRSS

05:02 EST 23rd January 2019 | BioPortfolio

UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary shares in an underwritten public offering. The company also intends to grant the underwriters a 30-day...

Human medicines European public assessment report (EPAR): Kentera (previously Oxybutynin Nicobrand), oxybutynin, Urinary Incontinence, Urge, Date of authorisation: 15/06/2004, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Kentera (previously Oxybutynin Nicobrand), oxybutynin, Urinary Incontinence, Urge, Date of authorisation: 15/06/2004, Revision: 16, Status: Authorised

MediQuant’s Success and Growth Strategy in Enterprise Active Archiving Earns the Market Leader a 2019 Northeast Ohio Leading Deal Maker Award

MediQuant®, the leading innovator and provider of enterprise active archiving solutions to hospitals and health systems, is the recipient of ACG Cleveland’s prestigious 2019 Northeast Ohio Leading Deal Maker Award. The award recognizes the region’s preeminent corporate deal makers for their accomplishments in using acquisitions, financings and other t...

Rainier Therapeutics Announces Oral Abstract Presentation on Fierce 21 Phase 2 Trial of Vofatamab in Metastatic Urothelial Cell Carcinoma (Bladder Cancer) at the 2019 ASCO Genitourinary Cancers Symposium

Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that data from its ongoing Phase 2 trial of its FGFR3-targeted antibody vofatamab will be presented at the upcoming 2019 ASCO Genitourinary Cancers Symposium taking place February 14-16, 2019 at the Moscone West Building in San Francisco. Presenta...

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS)

Prospective examination of the changes in the urinary microbiome induced by transrectal biopsy of the prostate using 16S rRNA gene analysis

CANCER de la PROSTATE et Maladie inflammatoire de l'intestin, 2 conditions fortement liées

La maladie inflammatoire de l'intestin (MICI) liée au cancer de la prostate, c’est la conclusion de cette étude de la Northwestern (Chicago). Des données qui alertent dans la revue European Urology alors que les hommes à MICI encourent un risque de cancer de la prostate multiplié par 4 à 5.   Les conclusions de cette […]

Approaches to urinary detection of prostate cancer

Machine learning detects, treats UTIs earlier

Scientists at the University of Surrey in Guildford, England, developed a tool that uses machine learning to identify and treat urinary tract infections at early stages in dementia patients, according to a study published in PLOS One.

In 2018, FDA approved an all-time record of 62 new therapeutic drugs (NTDs) [Not including diagnostic imaging agents, included are combination products with at least one new molecular entity as an active ingredient] with average Peak Sales per NTD $1.2Bi

In 2018, FDA approved an all-time record of 62 new therapeutic drugs (NTDs) [Not including diagnostic imaging agents, included are combination products with at least one new molecular entity as an active ingredient] with average Peak Sales per NTD $1.2Billion.   Reporter: Aviva Lev-Ari, PhD, RN BIOBUSINESS BRIEFS  15 JANUARY 2019 2018 FDA approvals hit all-time […]

Data Suggest That Men Should Resolve to Address Their BPH Symptoms in 2019

NeoTract Study Finds That Men Over 40 Are Not Aware that Delaying Treatment of Benign Prostatic Hyperplasia (BPH) Can Cause Permanent Bladder Damage or of Treatment Options NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced new data showing that both men and...

New Approaches in Removing Catalysts from API Slurries

NewsThere are increasing concerns about the safe handling of active pharmaceutical ingredients (APIs).Contributed Author: 

Grivas Discusses Developments in Bladder Cancer

Petros Grivas, MD, PhD, discusses the rapidly evolving field of locally advanced and metastatic bladder cancer.

Computer simulations reveal personalized treatment benefits kidney cancer patients

For early-stage kidney cancer patients who may be at risk for worsening kidney disease, personalized treatment plans such as undergoing active surveillance and MRI examinations may extend life expectancy, according to new research published Jan. 15 in Radiology.

FDA expanding cell & gene therapy review group. Agency says by '20, will have >200 cell or gene therapy INDs per year, adding to >800 active INDs on file. By 2025, "we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year.

FDA expanding cell & gene therapy review group. Agency says by '20, will have >200 cell or gene therapy INDs per year, adding to >800 active INDs on file. By 2025, "we predict that the FDA will be approving 10 to 20 cell and gene therapy products a year." https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm629493.htm …

Waters Accelerates Biomedical Research with Faster, More Accurate Amino Acid Analysis

Kairos Amino Acid Analysis Kit Simplifies and Automates LC/MS-MS Quantification of Amino Acids in Human Plasma and Urine Waters Corporation (NSE:WAT) today introduced a new amino acid analysis kit that reduces the time required to quantify amino acids, a critical application for research scientists investigating the physiological underpinnings of disea...

Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019

Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced that it will host its first R&D Day for investors and analysts in New York City on Thursday, February 7, 2019. The event will feature presentations by clinical experts in the field of urology, Dr. Ro...

Active Pharmaceutical Ingredient (API) Market, 2024 by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Active Pharmaceutical Ingredient/ API Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormone, Biosimilar) Drug (OTC, Rx), Therapy, and Region – Global Forecast to 2024” report has been added to ResearchAndMarkets.com’s offering. The … Continue reading →

New Peer Review Article Entitled “Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia” Published in Therapeutic Advances in Urology

HASBROUCK HEIGHTS, N.J., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that a new peer review article has been published in Therapeutic Advances in Urology. The new publication reviews current progress in the development of Fexapotide Triflutate, Nymox's first-in-class new molecular approach to managing the symptoms of benign prostatic hyperplas...

Physicians’ Education Resource® to Present Two Satellite Symposia at the 2019 ASCO Genitourinary Cancers Symposium

The programs will share insights on emerging clinical and scientific research on bladder cancer and renal cell carcinoma. Physicians’ Education Resource® (PER®), a leading resource for continuing medical education (CME), will conduct two CME-accredited satellite symposia on bladder cancer and renal cell carcinoma at the 2019 American Society of Cli...

Tencent's WeSure Launched WeFit Program, Invites Netizens to Get up, Get Active and Save with New "WeFit"

SHENZHEN, China, Jan. 14, 2019 /PRNewswire/ -- Tencent's insurance platform, WeSure, moves into the health management sector with the launch of the "WeFit" Health Plan (the "Plan"), a new discount-reward scheme inviting WeChat's 1.1 billion monthly active users to save money and have fun while getting fit. The new campaign was launched following the global roll-out of WeChat 7....

Calcineurin inhibitor Tacrolimus impairs host immune response against urinary tract infection

Turning the Tide on Opioid Prescribing Practices

As evidence grows that opioids may potentially worsen oncologic outcomes, surgeons and oncology providers must take an active role in addressing the opioid crisis by adopting similar protocols that decrease the quantity of narcotics available for diversion while ensuring safe patient care.

Women’s Excellence Obstetrics and Gynecology Specializes in Minimally Invasive Excision of Endometriosis

Excision of Endometriosis is considered the Gold Standard in Endometriosis Treatment for women DETROIT (PRWEB) January 11, 2019 Women’s Excellence specializes in the excision of endometriosis, the preferred treatment of endometriosis to remove inflammatory endometriosis tissue, relieve pain, and help restore fertility. Endometriosis is a disease in which endometrial tissue grows outside of the ...

Expert Discusses Neoadjuvant Chemo, Cystectomy in Localized Bladder Cancer

Jonathan L. Wright, MD, MS, FACS, highlights the available therapies for patients with localized muscle-invasive bladder cancer.

Advertisement
Quick Search
Advertisement
Advertisement

 

review and buy Urology market research data and corporate reports here